Posts

Sanofi floats flu shot marketing pledges to pacify EU antitrust probe

Sanofi has offered marketing commitments to the European Commission to address antitrust concerns over its flu vaccine campaign. The EU probe centers on allegations that Sanofi disparaged rival CSL Seqirus's Fluad vaccine while promoting its own Efluelda shot in France and Germany. Sanofi's proposed pledges include public statements and marketing restrictions until March 2030, and third parties have until August 21, 2026, to comment on them. Sources: EU Commission opens antitrust probe into Sanofi's flu vaccine ... European Commission Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine Sanofi Probed by EU Over Flu Vaccine Marketing - Morningstar Antitrust regulators probe Sanofi for allegedly disparaging a rival flu ... Sanofi Raided by EU in ‘Disparagement' Antitrust Case (1) Sanofi says under investigation by European Commission over vaccines EU opens antitrust probe over Sanofi flu vaccine marketing. Sanofi Probed by EU...

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

AZ, Ionis Shares Tumble on ATTR‑CM Trial Flop, But Analyst Flags Over‑Reaction Explained

GSK cuts losses on $700M Alzheimer’s pact with Alector after two clinical failures

Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

Independent Pharmacies Sue Prime Therapeutics Over Alleged Price‑Fixing Scheme with Express Scripts

AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical - Recent News

Creative Biolabs Launches End-to-End AI-Driven Antibody Solutions to Accelerate Biotherapeutic Discovery and Engineering

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

Satellos Shares Early Adult Data for Duchenne Pill Ahead of Key Pediatric Readout

MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy

Top performers of the second quarter 2026: chips, AI, and Asia lead gains

Lumvoa emerges as strong Tepezza rival—but SC Tepezza looms on the horizon